To include your compound in the COVID-19 Resource Center, submit it here.

Therapeutically adjacent

BMS acquires Amira to harvest two programs adjacent to core disease areas

Bristol-Myers Squibb Co.'s acquisition of Amira Pharmaceuticals Inc. appears at first blush to net a single compound that has completed Phase I testing in a completely new disease area for the pharma, along with some preclinical assets. But what BMS sees are two programs around relatively new pathways with potential to treat sequelae of diseases in the pharma's core therapeutic areas.

BMS is paying $325 million up front plus up to $150 million in milestones for

Read the full 758 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE